
Blog
MaxCyte signs strategic platform license with LG Chem to advance its allogeneic CAR-T programs
MaxCyte, Inc, a commercial cell engineering company specializing in the
MaxCyte, Inc, a commercial cell engineering company specializing in the
Researchers examined two cohorts of patients who received CD19-directed CAR-T
GC012F (Gracell Biotechnologies) is an autologous, genetically engineered, bispecific CAR-T
Many drugs cannot cross the blood-brain barrier (BBB), which also
GC012F is an autologous, genetically engineered, bispecific CAR-T that targets
Jin-Soo Kim’s team has discovered how to edit the mitochondrial
Researchers have shown that a synthetic IL-9 receptor allows anti-cancer
A major drawback of CRISPR-Cas9-mediated genome editing is that not
Genetically modified immune cells successfully target specific cancer cells that